Fig. 7

ADNVs strengthen the immunotherapy efficacy of PD-L1 blockade in mice. C57BL/6 mice were implanted with LLC cells for 7 days, and then instilled with ADNVs (25 mg/kg), alone or with αPD-L1 antibody, every 3 days for 2 weeks. Tumors were collected at day 21 post-implantation. A Gross photos of tumors at the end of experiments. B Tumor growth profiles in mice. ***p < 0.001 (Two-way ANOVA and Bonferroni post-tests). C Tumor weights at the end of the experiment. *p < 0.05, ***p < 0.001 (One-way ANOVA and Tukey’s significant difference post hoc test). D Immunoblotting of STING and downstream signaling molecules in TAMs; E Flow cytometry and quantification of the portions of M1 (CD86⁺) and M2 (CD206⁺) population in TAMs. *p < 0.05, **p < 0.01, ***p < 0.001 (One-way ANOVA and Tukey’s significant difference post hoc test). F Immunofluorescence staining of CD4⁺ and CD8⁺ cells in tumors. Nuclei: DAPI; Scale bar = 50 μm. The results are from one of two independent experiments. Representative images are shown and the data are presented as means ± SEM